Speckle tracking echocardiography in cardiac amyloidosis

Stricagnoli, Mario; Cameli, Matteo; Incampo, Eufemia; Lunghetti, Stefano; Mondillo, S.

doi:10.1007/s10741-019-09796-z

Cited by 27 publications

(26 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Proposed mechanisms include: 1. a reduced infiltration with amyloid fibrils at the apex, compared to basal segments; 2. an increased tendency towards apoptosis at basal level, as a result of the higher parietal stress [25,28,33]. This typical appearance was first described in late-stage CA, but there are studies that suggest its presence in less affected hearts [31,34]. 2D STE is helpful in differentiating the thickness of myocardium caused by amyloidosis from a real left ventricular hypertrophy.…”

Section: Speckle-tracking Echocardiographymentioning

confidence: 93%

“…Speckle tracking imagining in CA reveals reduced longitudinal shortening at the basal and mid-ventricular level with preserved longitudinal function at the apex [31]. This pattern, described by Phelan et al as 'relative apical sparing' is a helpful tool, both sensitive and specific, to make a diagnosis of CA [32].…”

Section: Speckle-tracking Echocardiographymentioning

confidence: 93%

“…The speckle-tracking echocardiography (STE) plays a major role in evaluation of patients with CA, being a sensitive echocardiographic technique which detects cardiac damage due to amyloid infiltration from early stages, even when other classic parameters are still in range [30]. In patients with CA, a reduced global longitudinal strain can be observed when the left ventricular ejection fraction is still preserved [31].…”

Section: Speckle-tracking Echocardiographymentioning

confidence: 99%

See 2 more Smart Citations

Cardiac Amyloidosis

Eötvös¹,

Paștiu²,

Zehan³

et al. 2021

Cardiomyopathy - Disease of the Heart Muscle

View full text Add to dashboard Cite

Amyloidosis represents a heterogeneous group of disorders caused by amyloid fibril deposition in the extracellular space in different organs. Among the many types of amyloidosis cardiac involvement occurs almost exclusively with immunoglobulin light chain amyloidosis (AL amyloidosis) or transthyretin amyloidosis (ATTR amyloidosis). When present cardiac amyloidosis (CA) has a significant impact on disease prognosis. The typical clinical presentation in CA is that of a restrictive cardiomyopathy. Clinical suspicion of CA is based on clinical, laboratory and electrocardiographic findings. The diagnosis is confirmed using echocardiography, cardiac magnetic resonance imaging, biopsy, and/or bone scintigraphy. A precise definition of amyloidosis type is essential for choosing the specific treatment for this condition. Treatment of CA has two components: general treatment of congestive HF, and specific treatment of the underlying protein misfolding disorder.

show abstract

Section: Speckle-tracking Echocardiographymentioning

confidence: 93%

Section: Speckle-tracking Echocardiographymentioning

confidence: 93%

Section: Speckle-tracking Echocardiographymentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Amyloidosis

Eötvös¹,

Paștiu²,

Zehan³

et al. 2021

Cardiomyopathy - Disease of the Heart Muscle

View full text Add to dashboard Cite

show abstract

“…Recently, speckle tracking echocardiography has been shown to be a useful modality for identifying CA (35)(36)(37). The condition of a relatively preserved longitudinal strain of the apex is called an apical sparing pattern, which is characteristic of CA, unlike other diseases with left ventricular hypertrophy (35)(36)(37).…”

Section: Echocardiographymentioning

confidence: 99%

How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage

et al. 2021

View full text Add to dashboard Cite

Cardiac involvement of systemic amyloidosis is preferentially observed in patients with amyloid light chain amyloidosis or transthyretin amyloidosis (ATTR). Owing to the development of diagnostic modalities and changes in recognition by physicians, transthyretin cardiac amyloidosis (ATTR-CA) is now understood to be a more common cause of heart failure than previously thought. Recent progress in disease-modifying therapeutic interventions, such as transthyretin stabilizers, has resulted in ATTR-CA changing from an incurable disease to a curable disease. These interventions are particularly effective in patients with mild symptoms of heart failure, thus indicating that early detection and a precise diagnosis are important for improving the prognosis. In this review article, we summarize the recent reports of early screening of ATTR-CA and describe some important points regarding the making of a precise diagnosis, especially focusing on histological evaluations.

show abstract

“…Consistent with these characteristics, pathologic CH plays a compensatory role by increasing cardiac overload during the early stages. However, a sustained pathological hypertrophic response eventually leads to systolic dysfunction 4 . Therefore, CH is a predictor of many cardiovascular diseases and death in humans 5 .…”

Section: Introductionmentioning

confidence: 99%

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt

Zhang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Cardiac hypertrophy (CH) is an independent risk factor for many cardiovascular diseases, and is one of the primary causes of morbidity and mortality in elderly people. Pathological CH involves excessive protein synthesis, increased cardiomyocyte size, and ultimately the development of heart failure. Myotubularin-related protein 14 (MTMR14) is a member of the myotubularin (MTM)-related protein family, which is involved in apoptosis, aging, inflammation, and autophagy. However, its exact function in CH is still unclear. Herein, we investigated the roles of MTMR14 in CH. We show that MTMR14 expression was increased in hypertrophic mouse hearts. Mice deficient in heart MTMR14 exhibited an aggravated aortic-banding (AB)-induced CH phenotype. In contrast, MTMR14 overexpression prevented pressure overload-induced hypertrophy. At the molecular level, prevention of CH in the absence of MTMR14 involved elevations in Akt pathway components, which are key elements that regulate apoptosis and cell proliferation. These results demonstrate that MTMR14 is a new molecular target for the treatment of CH.

show abstract

Speckle tracking echocardiography in cardiac amyloidosis

Cited by 27 publications

References 47 publications

Cardiac Amyloidosis

Cardiac Amyloidosis

How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage

Myotubularin-related protein 14 suppresses cardiac hypertrophy by inhibiting Akt

Contact Info

Product

Resources

About